Ngā hua rapu - Busaidy, Naifa

Whakamahine hua
  1. 1
    The Year in Medical Thyroidology Review: Current Challenges and Future Directions

    The Year in Medical Thyroidology Review: Current Challenges and Future Directions mā Busaidy, Naifa Lamki

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

    Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease mā Busaidy, Naifa Lamki, Cabanillas, Maria E.

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib

    Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib mā Shawa, Hassan, Busaidy, Naifa L, Schellingerhout, Dawid, Habra, Mouhammed Amir

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer

    Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer mā Cabanillas, Maria E., Hu, Mimi I., Durand, Jean-Bernard, Busaidy, Naifa L.

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?

    Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metast... mā Waguespack, Steven G., Tewari, Sanjit O., Busaidy, Naifa L., Zafereo, Mark E.

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Safe and Effective Dosing of Basal–Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorubicin, Vincristine, and Dexamethasone Chemotherapy

    Safe and Effective Dosing of Basal–Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorubicin, Vincristine, and Dexamethasone Chemotherapy mā Brady, Veronica, Thosani, Sonali, Zhou, Shouhou, Bassett, Roland, Busaidy, Naifa Lamki, Lavis, Victor

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer

    Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer mā Fabbro, Egidio Del, Dev, Rony, Cabanillas, Maria E., Busaidy, Naifa L., Rodriguez, EdenMae C., Bruera, Eduardo

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility

    OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety... mā Cabanillas, Maria, Busaidy, Naifa, Dadu, Ramona, Ferrarotto, Renata, Gross, Neil, Gule-Monroe, Maria, Lu, Charles, Grosu, Horiana, Williams, Michelle, Zafereo, Mark

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway mā Busaidy, Naifa L., Farooki, Azeez, Dowlati, Afshin, Perentesis, John P., Dancey, Janet E., Doyle, Laurence A., Brell, Joanna M., Siu, Lillian L.

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer–Related Diarrhea and Its Effects on Quality of Life: A Pilot Study

    Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer–Related Diarrhea and Its Effects on Quality of Life: A Pilot Study mā Dadu, Ramona, Hu, Mimi I., Cleeland, Charles, Busaidy, Naifa L., Habra, Mouhammed, Waguespack, Steven G., Sherman, Steven I., Ying, Anita, Fox, Patricia, Cabanillas, Maria E.

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience

    Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience mā Tsimberidou, Apostolia Maria, Vaklavas, Christos, Wen, Sijin, Hong, David, Wheler, Jennifer, Ng, Chaan, Naing, Aung, Tse, Susan, Busaidy, Naifa, Markman, Maurie, Sherman, Steven I., Kurzrock, Razelle

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Cushing's syndrome secondary to ectopic ACTH secretion: The University of Texas MD Anderson Cancer Center Experience

    Cushing's syndrome secondary to ectopic ACTH secretion: The University of Texas MD Anderson Cancer Center Experience mā Ejaz, Shamim, Vassilopoulou-Sellin, Rena, Busaidy, Naifa L., Hu, Mimi I., Waguespack, Steven G., Jimenez, Camilo, Ying, Anita K., Cabanillas, Maria, Abbara, Maher, Habra, Mouhammed Amir

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease

    MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease mā Gammons, Sarah, Hu, Mimi I, Zafereo, Mark E, Busaidy, Naifa L, Perrier, Nancy D, Bassett, Roland L, Hyde, Samuel M, Grubbs, Elizabeth G, Waguespack, Steven G

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

    Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors mā Cabanillas, Maria E., Dadu, Ramona, Iyer, Pryianka, Wanland, Kacey B., Busaidy, Naifa L., Ying, Anita, Gule-Monroe, Maria, Wang, Jennifer R., Zafereo, Mark, Hofmann, Marie-Claude

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer

    Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer mā Tam, Samantha, Amit, Moran, Boonsripitayanon, Mongkol, Cabanillas, Maria E., Busaidy, Naifa L., Gunn, G. Brandon, Lai, Stephen Y., Gross, Neil D., Sturgis, Erich M., Zafereo, Mark E.

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer

    Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer mā Amit, Moran, Tam, Samantha, Boonsripitayanon, Mongkol, Cabanillas, Maria E., Busaidy, Naifa L., Grubbs, Elizabeth Gardner, Lai, Stephen Y., Gross, Neil D., Sturgis, Erich M., Zafereo, Mark E.

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

    Immune-Related Thyroiditis with Immune Checkpoint Inhibitors mā Iyer, Priyanka C., Cabanillas, Maria E., Waguespack, Steven G., Hu, Mimi I., Thosani, Sonali, Lavis, Victor R., Busaidy, Naifa L., Subudhi, Sumit K., Diab, Adi, Dadu, Ramona

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine

    Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine mā Jaber, Tania, Waguespack, Steven G, Cabanillas, Maria E, Elbanan, Mohamed, Vu, Thinh, Dadu, Ramona, Sherman, Steven I, Amit, Moran, Santos, Elmer B, Zafereo, Mark, Busaidy, Naifa L

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier

    MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier mā Waguespack, Steven, Busaidy, Naifa, Hu, Mimi, Grubbs, Elizabeth, Weitzman, Steven, Wirth, Lori, Zafereo, Mark, Babiarz, Joshua, Hao, Yangyang, Huang, Jing, Kennedy, Giulia, Walsh, P. Sean, Kloos, Richard

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer

    Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer mā Dadu, Ramona, Waguespack, Steven G., Sherman, Steven I., Hu, Mimi I., Busaidy, Naifa L., Jimenez, Camilo, Habra, Mohammed A., Ying, Anita K., Bassett, Roland L., Cabanillas, Maria E.

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: